Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004166 · ClinicalTrials.gov registry record · Phase 3
Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy
A Phase 3 study of Ovarian Cancer and Quality of Life, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 1
- Study location
NCT00004166 is a Phase 3 study of Ovarian Cancer and Quality of Life that has completed, run by Northwestern University. The trial reports 1 study location across 1 state.
The verdict
NCT00004166, a Phase 3 study of Ovarian Cancer and Quality of Life, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1
- Study location
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase III trial to study the effectiveness of amifostine in treating patients who have ovarian epithelial cancer and who are receiving chemotherapy.
Conditions Studied
Interventions
- PROCEDURE quality-of-life assessment
- DRUG amifostine trihydrate
Study Locations (1)
Illinois
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Start Date | 1999-10 |
| Est. Completion | 2003-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004166
The ClinicalTrials.gov registry entry for NCT00004166 describes a study currently listed as completed, categorized as Phase 3. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which quality-of-life assessment is the first listed.
NCT00004166 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT00004166 about?
NCT00004166 is a clinical study titled "Amifostine in Treating Patients With Ovarian Epithelial Cancer Who Are Receiving Chemotherapy". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Randomized phase III trial to study the effectiveness of amifosti...
What is the current status of trial NCT00004166?
This trial is currently completed. It is a Phase 3 study. The study started on 1999-10. Estimated completion is 2003-01.
What conditions does trial NCT00004166 study?
This clinical trial studies the following conditions: Ovarian Cancer, Quality of Life.
What interventions are being tested in trial NCT00004166?
The interventions under investigation include: quality-of-life assessment (PROCEDURE), amifostine trihydrate (DRUG).
Who is sponsoring clinical trial NCT00004166?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00004166 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)
RECRUITING · Phase 3
-
Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RECRUITING · Phase 3
-
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 3
-
Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)
RECRUITING · Phase 3
-
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.